BackgroundAdipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy.For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia.BackgroundAdipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy.For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia.MethodsWe considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases.We collected SAT and total RNA was extracted and ATGL, HSL, PPAR alpha, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5.MethodsWe considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases.We collected SAT and total RNA was extracted and ATGL, HSL, PPAR alpha, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5.ResultsWe found higher expression of ATGL and HSL in GI cancer patients with respect to controls (p <= 0.008) and a trend of increase for PPAR alpha (p = 0.055). We found an upregulation of ATGL in GI cancer patients with cachexia (p = 0.033) and without cachexia (p = 0.017) vs controls. HSL was higher in patients with cachexia (p = 0.020) and without cachexia (p = 0.021), compared to controls. ATGL was upregulated in gastric cancer vs controls (p = 0.014) and higher HSL was found in gastric (p = 0.008) and in pancreatic cancer (p = 0.033) vs controls. At the protein level, we found higher CGI-58 in cancer vs controls (p = 0.019) and in cachectic vs controls (p = 0.029), as well as in gastric cancer vs controls (p = 0.027).ConclusionIn our cohort of GI cancer patients, we found a modulation in the expression of genes and proteins involved in lipolysis, and differences were interestingly detected according to cancer type.
Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer / Tambaro, Federica; Imbimbo, Giovanni; Ferraro, Elisabetta; Andreini, Martina; Belli, Roberta; Amabile, Maria Ida; Ramaccini, Cesarina; Lauteri, Giulia; Nigri, Giuseppe; Muscaritoli, Maurizio; Molfino, Alessio. - In: CANCER & METABOLISM. - ISSN 2049-3002. - 12:1(2024). [10.1186/s40170-023-00329-9]
Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer
Tambaro, Federica;Imbimbo, Giovanni;Andreini, Martina;Amabile, Maria Ida;Ramaccini, Cesarina;Lauteri, Giulia;Nigri, Giuseppe;Muscaritoli, Maurizio;Molfino, Alessio
2024
Abstract
BackgroundAdipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy.For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia.BackgroundAdipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy.For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia.MethodsWe considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases.We collected SAT and total RNA was extracted and ATGL, HSL, PPAR alpha, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5.MethodsWe considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases.We collected SAT and total RNA was extracted and ATGL, HSL, PPAR alpha, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5.ResultsWe found higher expression of ATGL and HSL in GI cancer patients with respect to controls (p <= 0.008) and a trend of increase for PPAR alpha (p = 0.055). We found an upregulation of ATGL in GI cancer patients with cachexia (p = 0.033) and without cachexia (p = 0.017) vs controls. HSL was higher in patients with cachexia (p = 0.020) and without cachexia (p = 0.021), compared to controls. ATGL was upregulated in gastric cancer vs controls (p = 0.014) and higher HSL was found in gastric (p = 0.008) and in pancreatic cancer (p = 0.033) vs controls. At the protein level, we found higher CGI-58 in cancer vs controls (p = 0.019) and in cachectic vs controls (p = 0.029), as well as in gastric cancer vs controls (p = 0.027).ConclusionIn our cohort of GI cancer patients, we found a modulation in the expression of genes and proteins involved in lipolysis, and differences were interestingly detected according to cancer type.File | Dimensione | Formato | |
---|---|---|---|
Tambaro_Assessment-lipolysis_2024.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.25 MB
Formato
Adobe PDF
|
1.25 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.